Actos (Pioglitazone) Compounding Legal Status, FDA Approval, and Safety

What Is Pioglitazone and How Did It Get FDA Approval?

Pioglitazone is an oral thiazolidinedione that activates peroxisome proliferator-activated receptor gamma (PPAR-gamma), improving insulin sensitivity in muscle, fat, and liver tissue. The FDA approved Actos (pioglitazone hydrochloride) tablets on July 15, 1999, under NDA 021073, for adults with type 2 diabetes mellitus as an adjunct to diet and exercise. [1] Takeda Pharmaceuticals held the original new drug application; multiple generic manufacturers now supply the U.S. Market.

The Original NDA and Pre-Approval Evidence

The NDA 021073 submission included key 26-week monotherapy trials and combination studies with sulfonylureas and insulin. Fasting plasma glucose fell by 30 to 60 mg/dL versus placebo in these early trials, and HbA1c dropped by approximately 1.0 to 1.6 percentage points depending on baseline glycemia and regimen. [2]

Approved Indications and Labeled Doses

The approved doses are 15 mg, 30 mg, and 45 mg tablets taken once daily, with or without food. The label permits pioglitazone as monotherapy or in combination with metformin, a sulfonylurea, or insulin. The maximum labeled dose is 45 mg/day. The FDA has not approved pioglitazone for type 1 diabetes, diabetic ketoacidosis, or pediatric patients under 18 years of age. [1]

Generic Entry and Market Availability

Patent protection for Actos expired in 2012. By 2013, at least six generic manufacturers had received FDA approval for pioglitazone tablets. As of 2025, 15 mg, 30 mg, and 45 mg tablets appear on the FDA's Orange Book as therapeutically equivalent (AB-rated) to the reference listed drug. [2] This broad commercial availability is the single most consequential regulatory fact for any compounding question.

Can Pioglitazone Be Legally Compounded?

Pioglitazone cannot be routinely compounded by 503A pharmacies or manufactured in bulk by 503B outsourcing facilities under current federal law. The drug is commercially available, reasonably priced, and not on the FDA's 503B bulk drug substances list or the 503A "clinical need" list. Compounding a commercially available drug without a documented patient-specific reason that cannot be met by the approved product violates the Federal Food, Drug, and Cosmetic Act (FD&C Act) Sections 503A and 503B. [3]

How 503A and 503B Rules Apply to Pioglitazone

Under FD&C Act Section 503A, a licensed pharmacist may compound for an individual patient only when the finished product is not essentially a copy of a commercially available drug. The FDA considers a compounded preparation an "essentially a copy" if it contains the same active ingredient(s) in the same route and dose range as an approved product and no clinical difference has been documented. [3]

Pioglitazone tablets at 15, 30, and 45 mg are commercially available, manufactured to GMP standards, and dispensed at low cost. A prescriber who writes a compounding prescription for pioglitazone 30 mg oral tablets must document a specific patient-level reason the approved tablet cannot be used. Examples that courts and the FDA have accepted in analogous cases include a verified allergy to a listed excipient and a documented need for an alternative dose form (e.g., a liquid for a patient unable to swallow). Absent such documentation, the prescription does not meet 503A criteria. [3]

Section 503B outsourcing facilities may compound only from bulk drug substances that appear on FDA's affirmatively nominated and evaluated list. Pioglitazone does not appear on that list as of July 2025. A 503B facility that manufactures bulk pioglitazone preparations is operating outside its statutory authority. [4]

The "Shortage" Exemption Does Not Apply

One common misunderstanding is that a drug shortage triggers open compounding rights. Under FD&C Act 503B, shortage status allows outsourcing facilities to compound copies of commercially available drugs only when the FDA has officially listed the drug on its current drug shortage database. Pioglitazone has not appeared on the FDA Drug Shortages database at any point in the past decade. [5] Generic supply is strong across multiple national wholesalers and retail pharmacies, with GoodRx pricing for 30-count pioglitazone 30 mg tablets consistently below $15.

What Compounders Can Legitimately Do

A 503A pharmacy can prepare a pioglitazone oral suspension (a dose form not commercially available) for a patient who cannot swallow tablets, provided the prescriber documents this clinical need. The compounded suspension must still use an FDA-approved bulk API, must not be made in bulk for office stock, and must be dispensed only on a patient-specific prescription. No 503B outsourcing facility may produce pioglitazone preparations for general distribution without the drug appearing on the affirmative 503B list. [3][4]

What the Actos Label Says: Key Prescribing Information

The FDA-approved prescribing information for pioglitazone carries several warnings that directly affect how the drug should be monitored and prescribed. These are not minor precautions. The bladder cancer warning, in particular, shaped two decades of post-market surveillance.

Bladder Cancer Warning

The most prominently debated label section concerns bladder cancer. The FDA first added a warning in 2011, following interim data from an employer-based cohort study and findings from the French national pharmacovigilance program, which reported a statistically significant increase in bladder cancer incidence in patients who had used pioglitazone for more than 12 months. [6]

The current label states that patients who have active bladder cancer should not use pioglitazone, and the drug should be used with caution in patients with a prior history of bladder cancer. Prescribers are instructed to evaluate patients for hematuria before starting therapy. [1]

The FDA's 10-year follow-up analysis of the KPNC (Kaiser Permanente Northern California) cohort, published in 2016, found a hazard ratio of 1.06 (95% CI 0.89 to 1.26) for bladder cancer in pioglitazone users versus non-users after adjusting for potential confounders, which did not reach statistical significance. [7] That result modestly attenuated the earlier signal without eliminating it, so the label warning remains.

Heart Failure and Fluid Retention

Pioglitazone causes dose-related fluid retention by increasing renal sodium reabsorption, and this effect can precipitate or worsen congestive heart failure. The label carries a boxed warning about heart failure. Pioglitazone is contraindicated in patients with NYHA Class III or IV heart failure. [1] In the PROactive trial (N=5,238), edema occurred in 22.0% of pioglitazone patients versus 13.5% of placebo patients, and heart failure requiring hospitalization occurred in 5.7% versus 4.1%, respectively. [8]

Hepatotoxicity and Liver Monitoring

Troglitazone, the first thiazolidinedione, was withdrawn from the market in 2000 due to severe hepatotoxicity, including fulminant liver failure. Pioglitazone has a substantially different hepatic safety profile. Post-market surveillance and controlled trial data have not demonstrated the same pattern of idiosyncratic liver injury seen with troglitazone. [1] The label recommends against initiating pioglitazone in patients with hepatic impairment and advises obtaining liver function tests if symptoms of hepatic dysfunction arise. Routine periodic liver function monitoring is no longer mandated in the label, though many clinicians continue it at baseline and annually.

Additional Label Warnings

The label also addresses the following:

• Macular edema: Case reports of macular edema have been associated with pioglitazone and other TZDs. Patients reporting visual disturbances should undergo prompt ophthalmologic evaluation.
• Fracture risk: Women taking pioglitazone have shown increased rates of distal limb fractures. The PROactive and other long-term trials documented this effect. Bone density monitoring is reasonable in post-menopausal women on long-term therapy.
• Ovulation induction: Pioglitazone, like other insulin sensitizers, may cause resumption of ovulation in anovulatory pre-menopausal women with insulin resistance. Contraception counseling is appropriate.
• Hypoglycemia: Pioglitazone alone does not cause hypoglycemia. Hypoglycemia risk increases when it is combined with insulin or a sulfonylurea.

Pioglitazone Safety: Post-Market Surveillance Data

Post-market surveillance of pioglitazone spans more than 25 years and is among the most extensive in oral diabetes pharmacology. The drug's safety record is mixed: it improves metabolic markers but carries the bladder cancer signal and cardioedema risk discussed above.

PROactive Trial Cardiovascular Outcomes

The PROactive trial (Prospective Pioglitazone Clinical Trial In Macrovascular Events, N=5,238) randomized patients with type 2 diabetes and existing macrovascular disease to pioglitazone 45 mg or placebo over 34.5 months. The primary composite endpoint (all-cause mortality, non-fatal MI, stroke, acute coronary syndrome, leg amputation, coronary revascularization, and leg revascularization) did not differ significantly between groups (HR 0.90, 95% CI 0.80 to 1.02, P=0.095). [8] The secondary composite of all-cause mortality, non-fatal MI, and stroke favored pioglitazone (HR 0.84, 95% CI 0.72 to 0.98, P=0.027). This secondary outcome has influenced off-label use in high-cardiovascular-risk patients, though it was a pre-specified secondary endpoint.

PIVENS Trial: Pioglitazone in NASH

The PIVENS trial (Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis, N=247) compared pioglitazone 30 mg/day, vitamin E 800 IU/day, and placebo in patients with biopsy-confirmed NASH who did not have diabetes. After 96 weeks, 34% of pioglitazone-treated patients met the primary histologic improvement endpoint versus 19% on placebo (P=0.04). [9] Fibrosis scores also improved significantly in the pioglitazone arm. These findings have driven substantial off-label prescribing for NASH, particularly in patients with concurrent insulin resistance or prediabetes.

Pioglitazone Prescribing Decision Framework for Off-Label NASH Use

The following framework reflects current evidence and guideline positions for clinicians considering pioglitazone in NASH (non-diabetic patients):

| Patient Profile | Pioglitazone Suitability | Notes | |---|---|---| | Biopsy-confirmed NASH, no diabetes, no prior bladder cancer | Supported by PIVENS data | 30 mg/day; monitor weight, edema | | NASH with prediabetes or T2DM | Supported; also addresses glycemia | Start 15 mg, titrate to 30 mg | | NASH with NYHA Class III/IV CHF | Contraindicated | Fluid retention risk unacceptable | | NASH with active or recent bladder cancer | Avoid | Label contraindication | | Post-menopausal woman, osteoporosis | Use with caution | Fracture risk data from PROactive |

The 2023 American Association for the Study of Liver Diseases (AASLD) guidance states: "Pioglitazone is recommended for use in patients with biopsy-proven NASH, with or without diabetes, given consistent histologic benefit across trials." [10] This recommendation is conditional and acknowledges the bladder cancer and fracture signals.

FDA Sentinel System Monitoring

The FDA's Sentinel System has monitored pioglitazone continuously since 2012, with particular attention to bladder cancer. A 2016 Sentinel analysis covering more than 193,000 pioglitazone users found an adjusted HR for bladder cancer of 1.06, consistent with the KPNC cohort result cited above. [7] The Sentinel data did not change the label warning but provided reassurance that the absolute risk increase, if real, is small.

Off-Label Use: PCOS, Prediabetes, and Metabolic Syndrome

Pioglitazone sees meaningful off-label use beyond NASH. In polycystic ovary syndrome (PCOS), a 2006 randomized trial (N=80) compared pioglitazone 30 mg/day with metformin 1,500 mg/day over 6 months. Both drugs reduced androgen levels and improved menstrual regularity, with pioglitazone showing a modest advantage in reducing free androgen index (p<0.05). [11] The Endocrine Society PCOS guideline (2023) does not list pioglitazone as a first-line agent, but notes it as an option for patients intolerant of metformin. [12]

In prediabetes, the ACT NOW trial (N=602) showed that pioglitazone 45 mg/day reduced progression from impaired glucose tolerance to type 2 diabetes by 72% (HR 0.28, 95% CI 0.16 to 0.49) over a median of 2.4 years, versus placebo. [13] The ADA Standards of Care acknowledge this evidence but do not recommend pioglitazone as a first-line prediabetes drug, citing the bladder cancer and weight gain signals. [14]

Pioglitazone Compared to Other Oral Antidiabetics: Where It Sits in Guidelines

The ADA Standards of Medical Care in Diabetes (2025 update) place pioglitazone as a secondary option in the type 2 diabetes algorithm, behind metformin, GLP-1 receptor agonists with cardiovascular benefit, and SGLT2 inhibitors with cardiovascular or renal benefit. [14] Pioglitazone is favored when cost is a dominant concern, when patients cannot tolerate injectable medications, or when the clinical picture includes significant hepatic steatosis.

Cost Advantage Over Newer Agents

A 30-day supply of pioglitazone 30 mg costs approximately $4 to $15 at major pharmacy chains, compared to $800 to $1,000 per month for branded GLP-1 receptor agonists without insurance. This cost differential is clinically meaningful in uninsured and underinsured populations. The ADA recognizes cost as a legitimate driver of drug selection in its tiered algorithm. [14]

Combination Products

The FDA has approved two combination tablets containing pioglitazone:

• Actoplus Met / Actoplus Met XR: Pioglitazone plus metformin (NDA 021842)
• Duetact: Pioglitazone plus glimepiride (NDA 021925)

Both combination products also have generic equivalents. The same compounding restrictions apply: these combinations are commercially available and therefore not eligible for routine 503A or 503B compounding.

Dispensing, Monitoring, and Patient Counseling Essentials

Dispensing pioglitazone requires attention to several practice points that flow directly from the label.

Baseline Evaluation Before Starting

Before the first prescription is filled, the prescriber should:

1. Assess for active or prior bladder cancer and document the finding.
2. Obtain baseline liver function tests if hepatic disease is suspected.
3. Evaluate for NYHA heart failure class.
4. Review bone density data in post-menopausal women planning long-term use.
5. Counsel pre-menopausal women about potential resumption of ovulation.

Ongoing Monitoring Schedule

Weight and edema should be assessed at each visit. Blood pressure monitoring matters because fluid retention can raise blood pressure even without overt edema. HbA1c should be checked at 3 months initially, then every 3 to 6 months depending on glycemic stability. Any new hematuria should prompt urologic evaluation before continuing the drug. [1]

Key Patient Counseling Points

• Swelling in the legs or sudden weight gain of more than 2 to 3 pounds in a day should be reported immediately.
• Blood in the urine, even once, warrants a call to the prescriber before the next dose.
• The drug takes 8 to 12 weeks to show its full glycemic effect; patients should not expect rapid glucose lowering in the first few weeks.
• Weight gain of 1 to 3 kg is common and expected, primarily from fluid retention and some fat redistribution.